Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | MMP8 | P22894 | 2/20 | 0.48 |
| ▸ | PPID | Q08752 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.43 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28186906 | 1.00 | SMN1; SMN2 (0.49) | SMN1; SMN2MMP8PPIDEPHX2PPARG | |
| SCHEMBL1781525 | 1.00 | SMN1; SMN2 (0.49) | SMN1; SMN2MMP8PPIDEPHX2PPARG | |
| Hydrochloric Acid SCHEMBL3366422 | 0.98 | SMN1; SMN2 (0.48) | SMN1; SMN2MMP8PPIDEPHX2PPARG | |
| Hydrochloric Acid SCHEMBL7323482 | 0.98 | SMN1; SMN2 (0.48) | SMN1; SMN2MMP8PPIDEPHX2PPARG | |
| SCHEMBL14776455 | 0.89 | PDCD1 (0.48) | MMP8MEN1KMT2APDCD1CD274 | |
| SCHEMBL14776768 | 0.88 | MEN1 (0.49) | SMN1; SMN2MMP8PPIDEPHX2PPARG | |
| SCHEMBL10519227 | 0.88 | PPID (0.43) | SMN1; SMN2PPIDMEN1KMT2APDCD1 | |
| SCHEMBL1839763 | 0.88 | ATM (0.55) | MAPTMEN1KMT2AATM | |
| SCHEMBL1526134 | 0.88 | ATM (0.55) | MAPTMEN1KMT2AATM | |
| SCHEMBL7856109 | 0.88 | ATM (0.55) | MAPTMEN1KMT2AATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200231532-A1 | Supported Metal Catalysts | JOHNSON MATTHEY PLC (GB) | 2020-07-23 | — | — | US | claimed |
| US-20180099923-A1 | Supported Metal Catalysts | JOHNSON MATTHEY PLC (GB) | 2018-04-12 | — | — | US | claimed |
| EP-2536500-B1 | SUPPORTED METAL CATALYSTS | JOHNSON MATTHEY PLC (GB) | 2016-12-07 | — | — | EP | claimed |
| US-20130072722-A1 | SUPPORTED METAL CATALYSTS | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2013-03-21 | — | — | US | claimed |
| EP-2536500-A1 | SUPPORTED METAL CATALYSTS | Johnson Matthey PLC (GB) | 2012-12-26 | — | — | EP | claimed |
| WO-2011101679-A1 | SUPPORTED METAL CATALYSTS | JOHNSON MATTHEY PLC (GB) | 2011-08-25 | — | — | WO | claimed |
| US-20200231532-A1 | Supported Metal Catalysts | JOHNSON MATTHEY PLC (GB) | 2020-07-23 | — | — | US | disclosed |
| US-20180099923-A1 | Supported Metal Catalysts | JOHNSON MATTHEY PLC (GB) | 2018-04-12 | — | — | US | disclosed |
| EP-1937252-B1 | COMPOSITIONS FOR STIMULATING NEUROGENESIS AND INHIBITING NEURONAL DEGENERATION | NEURONASCENT INC (US) | 2017-10-25 | — | — | EP | disclosed |
| US-9539261-B2 | Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration | NEURONASCENT, INC. (US) | 2017-01-10 | — | — | US | disclosed |
| EP-2536500-B1 | SUPPORTED METAL CATALYSTS | JOHNSON MATTHEY PLC (GB) | 2016-12-07 | — | — | EP | disclosed |
| US-20150209371-A1 | Methods and Compositions For Stimulating Neurogenesis and Inhibiting Neuronal Degeneration | NEURONASCENT, INC. | 2015-07-30 | — | — | US | disclosed |
| US-8999972-B2 | Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration | NEURONASCENT, INC. (US) | 2015-04-07 | — | — | US | disclosed |
| US-20030236225-A1 | Methods of use and compositions for the diagnosis and treatment of infectious disease | GOVERNMENT OF THE UNITED STATES OF AMERICA REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2003-12-25 | — | — | US | disclosed |
| WO-2003096989-A2 | ANTI TUBERCULAR DRUG: COMPOSITIONS AND METHODS | DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2003-11-27 | — | — | WO | disclosed |
| WO-2003024926-A2 | METHODS AND COMPOSITIONS OF NOVEL TRIAZINE COMPOUNDS | REDDY US THERAPEUTICS, INC. (US) | 2003-03-27 | — | — | WO | disclosed |
| US-5472698-A | Mixture of (N-acetyl)-L-serine, N-acetylcysteine and alpha-lipoic acid which promotes ceramide production in skin cells | ELIZABETH ARDEN CO., DIVISION OF CONOPCO, INC. (US) | 1995-12-05 | — | — | US | disclosed |
| US-4818749-A | Carboxyalkyl dipeptides and medical use thereof in treating hypertension and congestive heart failure | SCHERING CORPORATION (US) | 1989-04-04 | — | — | US | disclosed |
| US-4808573-A | ANGIOTENSIN CONVERTING ENZYME INHIBITORS | SCHERING CORPORATION (US) | 1989-02-28 | — | — | US | disclosed |
| US-4575503-A | ANGIOTENSIN CONVERTING ENZYME INHIBITOR, HYPOTENSIVE | CIBA-GEIGY CORPORATION (US) | 1986-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072722-A1 | SUPPORTED METAL CATALYSTS | SOD1, HNMT, SOD3 | SMN1; SMN2 2704/4885MMP8 3062/4885PPID 1862/4885 |
| US-20030236225-A1 | Methods of use and compositions for the diagnosis and treatment of infectious disease | TERT, C5, DERA | SMN1; SMN2 1018/4885MMP8 889/4885PPID 1912/4885 |
| US-20200231532-A1 | Supported Metal Catalysts | SOD1, HNMT, SOD3 | SMN1; SMN2 2704/4885MMP8 3062/4885PPID 1862/4885 |
| US-20150209371-A1 | Methods and Compositions For Stimulating Neurogenesis and Inhibiting Neuronal Degeneration | DCX, BDNF, GAP43 | SMN1; SMN2 143/4885MMP8 793/4885PPID 2453/4885 |
| US-20180099923-A1 | Supported Metal Catalysts | SOD1, HNMT, SOD3 | SMN1; SMN2 2704/4885MMP8 3062/4885PPID 1862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.